等待開盤 01-29 09:30:00 美东时间
+0.210
+9.59%
今日重点评级关注:Ascendiant Capital:维持SurgePays Inc"买入"评级,目标价从9.5美元升至9.75美元;Ascendiant Capital:维持Outlook Therapeutics"买入"评级,目标价从8美元升至10美元
2025-12-23 12:32
Jones Trading analyst Soumit Roy initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $7.
2025-12-22 20:25
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价;Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price target from $4 to $5.
2025-11-06 19:52
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 9.89 percent. This is a 54.55 percent increase over losses of $(0.22) per share
2025-11-06 06:02
Context Therapeutics Inc. announced its participation in two upcoming investor conferences: the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, November 10-12, 2025, featuring a Fireside Chat on November 10 at 3:00 PM ET and 1x1 meetings, and the Stifel 2025 Healthcare Conference in New York, November 11-13, 2025, with a presentation on November 12 at 10:00 AM ET and 1x1 meetings. A live webcast will be available on the Company’...
2025-10-28 11:30
The latest update is out from Context Therapeutics ( ($CNTX) ). Context Therape...
2025-10-21 06:25
今日重点评级关注:Rosenblatt:维持HIVE Digital Technologies"买入"评级,目标价从5美元升至10美元;摩根大通:维持Array Technologies"超配"评级,目标价从13美元升至15美元
2025-10-17 09:58
D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.
2025-10-16 20:40
Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced two posters will
2025-10-06 19:38